In total, 7 out of 203 BioCarta pathways were significantly enriched in TFAM-deficient compared to control colorectal cancer cells (false discovery rate (FDR) < 0.25; nominal p-value < 0.01). The gene discussed is TFAM; the disease is colorectal cancer.